Wave life sciences announces positive data from forward-53 clinical trial in dmd including significant functional benefit and reversal of muscle damage after 48 weeks of dosing with wve-n531

Statistically significant and clinically meaningful improvement of 3.8 seconds in time-to-rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including nsaa
WVE Ratings Summary
WVE Quant Ranking